Standard Medicare Prescription Drug Benefit, 2013
Standard Medicare Prescription Drug Benefit, 2013 Download Source Kaiser Family Foundation illustration based on CMS standard benefit parameter update for 2013. Amounts rounded to nearest dollar.
View the Latest: Medicare Part D
Filter
-
-
How Health Insurers and Brokers Are Marketing Medicare
ReportTo capture the state of television marketing activities and consider the implications for people with Medicare, KFF analyzed ad data compiled by the Wesleyan Media Project, that were obtained from Vivvix (formerly Kantar) CMAG, a data analytics and consulting firm, and were coded by the Wesleyan Media Project in collaboration with KFF. The data set included all English-language TV ads that aired across national and local markets on broadcast television or national cable, from October 1st, 2022, through December 7th, 2022, the period that includes the Medicare open enrollment period for coverage in 2023.
-
What to Know About the Medicare Open Enrollment Period and Medicare Coverage Options
Issue BriefEach year, Medicare beneficiaries have an opportunity to make changes to how they receive their Medicare coverage during the nearly 8-week annual open enrollment period. This brief answers key questions about the Medicare open enrollment period and Medicare coverage options.
-
KFF Research Shows that Medicare Open Enrollment TV Ads Are Dominated by Medicare Advantage Plans Featuring Celebrities, Active and Fit Seniors, and Promises of Savings and Extra Benefits Without Fundamental Plan Information
News ReleaseThe annual blitz of ads for Medicare Advantage plans has become a rite of fall, as health insurers, brokers and other third parties seek to court enrollees for these private plans, which are offered to the 65 million people with Medicare during the program’s open enrollment season.
-
KFF Health Tracking Poll July 2023: The Public’s Views Of New Prescription Weight Loss Drugs And Prescription Drug Costs
FeatureAbout half of adults are interested in taking prescription weight loss drugs. though interest drops when presented with obstacles or drawbacks. Many adults struggle with affording prescription drugs and say there should be more price regulation. Few are aware of provisions in the 2023 Inflation Reduction Act aimed at lowering the drug price for Medicare beneficiaries
-
Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing – Even Though Medicare Cannot Cover The Drugs for Weight Loss
News ReleaseA KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted indications, including to treat diabetes.
-
An Estimated 1 in 4 Medicare Beneficiaries With Obesity or Overweight Could Be Eligible for Medicare Coverage of Wegovy, an Anti-Obesity Drug, to Reduce Heart Risk
News ReleaseIn a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of Wegovy (semaglutide) now that the Food and Drug Administration has approved the use of the anti-obesity drug to reduce the risk of heart attacks and stroke in certain patients.
-
The New Help for Medicare Beneficiaries with High Drug Costs That Few Seem to Know About
Policy WatchThis policy watch highlights a change coming to the Medicare Part D drug benefit that will cap Part D enrollees' out-of-pocket drug costs, beginning in 2024, resulting in savings of thousands of dollars for high-cost drugs - a change that recent KFF tracking poll results show few older adults know about.
-
Medicare Part D in 2024: A First Look at Prescription Drug Plan Availability, Premiums, and Cost Sharing
Issue BriefMedicare Part D prescription drug coverage is available for people with Medicare who enroll in private plans, either a stand-alone prescription drug plan (PDP) for people in traditional Medicare, or a Medicare Advantage plan that covers all Medicare benefits, including prescription drugs (MA-PD). This issue brief provides an overview of Part D plan availability and premiums in 2024 and key trends over time.
-
Medicare Part D 2011 Data Spotlight: The Coverage Gap
ReportThis data spotlight examines the availability of gap coverage in the private Medicare Part D drug plans offered to beneficiaries in 2011, the first year of the phase-out of the gap, as required under the 2010 health reform law.